Incremento de supervivencia en melanoma - page 16

Robert et

. N Eng J Med 2015; Schachter et al. SMR 2015; Schachter ASCO 2016

Pembrolizumab

Ipilimumab

Keynote 006

ORR 37%

CR 12%

ORR 36%

CR 13%

ORR 13%

CR 5%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,6,7,8,9,10,11,12,13,14,15 17,18,19,20,21,22,23,24,25,26,...29